GW Pharma’s Latest Clinical Trial Successful, Stock Soars

420Patients.com is accepting qualified medical marijuana patients and caregivers to join our network. We value every registered member and we hope to serve you in Arizona. This article brought to you by 420 community friends mmjbusinessdaily.com

British cannabis company GW Pharmaceuticals has conducted a successful clinical trial in which it treated epileptic children with one of its marijuana-based drugs, triggering a surge in the company’s stock price.

According to Reuters, tested doses of GW Pharmaceutical’s drug Epidiolex “were found to have induced a statistically significant improvement in reducing seizures” in patients with a particular type of epilepsy during phase III clinical trials.

On Monday, after news of the trials broke, the publicly traded company’s stock shot up 16% to a record high of 811 pence on the London Stock Exchange, Reuters reported. The news

GW Pharma’s Latest Clinical Trial Successful, Stock Soars is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

Leave a Reply

Skip to toolbar